BMJ Support Palliat Care
Palliative Care Clinical Studies Collaborative (PaCCSC), University of Technology Sydney, Sydney, New South Wales, Australia
Published: January 2024
Objectives: To describe the contemporary real-world use of cyclizine for nausea or vomiting, and the associated benefits and harms.
Methods: This was a prospective, consecutive case series of routine clinical use of cyclizine for nausea or vomiting in palliative care conducted across 19 sites in Australia, Aotearoa/New Zealand and the UK. Clinical outcomes were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events at baseline and 72 hours after initiation of cyclizine. Ad hoc safety reporting continued for 2 weeks.
Results: Data were collected from 101 patients between May 2018 and December 2020. Cyclizine was mostly used in combination with another antiemetic. Overall, 79 patients benefited and 32 experienced harm (56 had benefit without harm; 9 had harm without benefit). The most common harms were constipation (13%), somnolence (9%) and confusion (7%), adding to the already high rates of these symptoms at baseline. For the four patients with serious harms (grade ≥3), these were exacerbations of existing symptoms. Nine patients stopped cyclizine at 72 hours and a further 20 patients within 2 weeks. The most common reasons for stopping were lack of benefit and symptom resolution; none stopped because of harms.
Conclusions: When used as described in a palliative care setting, cyclizine benefits about three-quarters of patients, with about one-third experiencing tolerable harms.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1136/spcare-2022-003795 | DOI Listing |
Int J Clin Pharm
January 2025
Department of Medicine, Evangelical University of Goiás, Avenida Universitária Km 3.5, Cidade Universitária, Anápolis, GO, 75083-515, Brazil.
Background: Recent studies suggest that duloxetine administration before non-laparoscopic surgery may reduce postoperative pain and analgesic requirement without increasing adverse event occurrence.
Aim: To perform a systematic review and meta-analysis of randomized controlled trials (RCTs) on preoperative administration of duloxetine versus placebo for postoperative pain relief in adults undergoing laparoscopic surgery, assessing efficacy- and safety-related outcomes.
Method: We systematically searched MEDLINE, Embase, and Cochrane Library, covering all records up to July 19, 2024.
Hernia
January 2025
Department of Clinical Science and Education Södersjukhuset, Karolinska Institutet, Stockholm, Sweden.
Purpose: The aim of this study was to evaluate risk factors for postoperative pain and nausea after open repair for primary ventral hernias.
Method: A population-based registry study was conducted based on data assembled from the Swedish national ventral hernia repair register between January 2016 and December 2021and cross-matched with the Swedish perioperative register.
Results: Altogether 2064 open ventral hernia repairs were registered, including 816 (39.
Rev Med Suisse
January 2025
Centre de médecine intégrative et complémentaire, Service d'anesthésiologie, Centre hospitalier universitaire vaudois, 1011 Lausanne.
This article reports on new findings on integrative and complementary medicine published in 2024. The implementation of guidelines for the management of pain in cancer patients is discussed. Then, a literature review is presented, that aims to clarify the role of complementary approaches in the management of chemotherapy-induced nausea and vomiting and provides a concrete example of how recommendations are established.
View Article and Find Full Text PDFClin Transl Radiat Oncol
March 2025
Department of Radiation Oncology, Bordeaux University Hospital, F33000 Bordeaux, France.
Purpose: Nausea is a common symptom in patients irradiated for benign brain tumors. The dorsal vagal complex (DVC) located in the brainstem (BS) has been identified as the center of nausea and vomiting. The objective of our study was to determine an association between mean dose to the DVC and nausea.
View Article and Find Full Text PDFJ Immunother Precis Oncol
February 2025
Sarah Cannon Research Institute at HealthONE, Denver, CO, USA.
Cyclin dependent kinase 2 (CDK2) is responsible for enforcing progression through the G1-S phase transition. Mutations and alterations in the CDK2 signaling pathway are associated with various cancers, most commonly breast, ovarian, prostate, leukemia, and lymphoma. CDK2 inhibitors have shown promising preclinical and early clinical results, and this class of agents may be most effective against cancers with cyclin E overactivity.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!
© LitMetric 2025. All rights reserved.